Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

A father and his doctor are set to cycle 450km to Paris to help fund a cure. Richard Sadler was diagnosed with myeloma, an incurable blood cancer, in 2021. On Thursday, September 26, the 61-year-old ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

A U.S. Navy veteran made “lemonade out of lemons” and used his cancer diagnosis to create a fundraiser for other vets.

LADENBURG, Germany - () - September 23, 2024 - Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Antengene receives Thailand FDA approval to commercialize Xpovio in Thailand: Shanghai Tuesday, September 24, 2024, 13:00 Hrs [IST] Antengene Corporation Limited, a leading innova ...